ClinicalTrials.gg
CompletedNCT04116658ROSALIEUpdated Nov 28, 2025Results posted

First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma

A Phase 1/2 interventional study of Multiple dose of EO2401 in Glioblastoma, Adult, sponsored by Enterome. Completed at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Enterome · Phase 1/2, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Glioblastoma with a site in Germany — 25 open to participants now, 37 under way, 8 of them phase 3. Glioblastoma · Germany.

Enrollment
59th of 112
100 · median 108
Started
2020
with 3 others
Phase 1/2
21 of 133
2 open now
Registered
90th of 133
by date

Among the 133 studies in Glioblastoma with a site in Germany, this one is the 59th largest by enrollment of the 112 interventional ones that give a count, is one of 4 that started in 2020, is one of 21 in phase 1/2, and was the 90th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

25 of the 133 studies in Glioblastoma with a site in Germany are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Glioblastoma with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.

Read the detailed description

This is a multicenter, Phase 1b/2a, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.

EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between Tumor Associated Antigens and microbiome-derived peptides that will be administered alone and in combination with nivolumab, and nivolumab/bevacizumab to generate preliminary safety and efficacy data in patients with progressive glioblastoma.

03

Conditions studied

  • Glioblastoma, Adult

Browse trials for

Keywords

  • Glioblastoma
  • Vaccine
  • Nivolumab
  • Bevacizumab
  • Safety
  • Tolerability
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with unequivocal documented (including histological confirmation of Glioblastoma-GB- at the primary diagnosis) evidence of first progression/recurrence of GB on MRI, as defined by RANO criteria
  2. Patients with :

    • for Cohorts 1, 2a, and 3: at least 1
    • for Cohort 2b: no measurable enhancing disease
    • for Cohort 2c: documented recurrence of GB deemed to be candidate for surgery
  3. Patients with an age ≥ 18 years old
  4. Patients who are human leukocyte antigen (HLA)-A2 positive
  5. Patients with an (ECOG) performance status ≤ 2 or performance status ≥ 70
  6. Patients should have received standard primary therapy, including surgery (, incomplete or complete resection), radiation, temozolomide, if applicable

    1. Radiation therapy must have been finished 28 days before first study treatment administration
    2. Patients who received temozolomide as therapy must have stopped the treatment and have a of 28 days before first study treatment administration (6 weeks for nitrosoureas and 5 half lives for experimental therapies)
    3. Patients with unmethylated methylguanine-DNA-methyltransferase (MGMT) promoter can be included even if they have not received temozolomide prior to the inclusion in this clinical study)
  7. Female patients of must have a negative serum pregnancy test within 72 hours prior to dosing
  8. Considering the embryofetal toxicity of the nivolumab shown on animals' models, the following recommendations for must be followed:

    a. If not surgically sterile, female patients of childbearing potential age must use highly effective contraception from signing the Form (ICF) through 6 months after the last treatment dose administered. Highly effective contraception included: i. Combined (estrogen and progesterone containing) hormonal contraception associated with inhibition of ovulation: Oral Intravaginal Transdermal ii. Progestogen-only hormonal contraception associated with inhibition of ovulation: Oral Injectable Implantable iii. Intrauterine device iv. Intrauterine hormone-releasing system v. Bilateral tubal occlusion vi. Sexual abstinence. In each case of delayed menstrual period (over 1 month between menstruations), confirmation of absence of pregnancy is strongly recommended. This recommendation also applies to women of childbearing potential with infrequent or irregular menstrual cycles.

    b. If not surgically sterile, male with female partner of childbearing potential must use condom from signing the ICF through 8 months after the last treatment dose administered. Males must ensure that their partners of childbearing potential use highly effective contraception also.

  9. Patients having received the information sheet and who have provided written informed consent prior to any study-related procedures
  10. Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures indicated in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Patients treated with dexamethasone > 2 mg/day or equivalent (i.e., 13 mg/day of prednisone) within 14 days before the first EO2401 administration, unless required to treat an adverse event (AE) Note: The criterion implios the patient should not receive treatment with dexamethasone > 2 mg/day or equivalent at the actual time of a screening visit (single time point assessment), and within 14 days before the first EO2401 administration (unless required to treat AE); the latter part of the criterion should be checked at the time of treatment start.
  2. 2. Patients treated with radiotherapy, and cytoreductive therapy within 28 days (6 weeks for nitrosoureas) before the first EO2401 administration. In addition, patients should not have received any prior treatment with compounds targeting , PD-L1, CTLA-4, or similar compounds where general resistance against therapeutic vaccination approaches might have developed; also, patients should not have received systemic anti-tumor treatment or radiotherapy for their progressive or first recurrent GB.
  3. Patients with tumors primarily located in the infra-tentorial segment
  4. Patients with known radiological evidence of extracranial
  5. Patients with presence of new hemorrhage (excluding, stable Grade 1) or uncontrolled seizure
  6. Patients with significant
  7. Patients with abnormal (≥ Grade 2 National Cancer Institute-Common Terminology Criteria for AEs [] version 5.0) laboratory values for hematology, liver, and renal function (serum creatinine). In detail, the following values apply as exclusion criteria:

    1. \< 10 g/dL (6.2 mmol/L)
    2. White blood cell count decrease (\< 3.0 × 109/L) or increase (> 10.0 × 109/L)
    3. decrease (\< 1.5 × 109/L)
    4. count decrease (\< 75 × 109/L)
    5. > 1.5 × per local laboratory levels; note, patients with hypothyroidism only requiring hormone replacement therapy are permitted to enroll, also patients with abnormal laboratory values judged by the treating physician as clinically non-relevant.
    6. > 3 × ULN
    7. Aspartate aminotransferase > 3 × ULN
    8. Serum creatinine increase (> 1.5 × ULN)
    9. Abnormal thyroid function
  8. For patients who are planned to receive bevacizumab:

    1. Patients with nephrotic syndrome
    2. Patients with proteinuria ≥ 2g/24 hours
    3. Patients with history or active gastrointestinal perforation and fistula
    4. Significant surgical procedure in the 4 weeks preceding the start of treatment or planned surgery
    5. Unhealed wound
    6. Patient with recent (4 weeks) history of hemoptysis of ½ teaspoon or more of red blood
    7. Thrombotic episode within 6 months
    8. Uncontrolled diabetes mellitus or hypertension
    9. Posterior reversible encephalopathy syndrome
  9. Patients with persistent Grade 3 or 4 toxicities (according to NCI-CTCAE v5.0). Toxicities must be resolved since at least 2 weeks to Grade 1 or less. However, alopecia or other persisting toxicities Grade ≤ 2 not constituting a safety risk based on Investigator's judgment is acceptable
  10. Patients with to contrast-enhanced MRI
  11. Other or prior malignancy with a disease-free interval of less than 3 years except those treated with surgical intervention and an expected low likelihood of recurrence such as basal cell or squamous cell skin cancer, or carcinoma in situ. Patients with adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ are eligible
  12. 12. Patients with active infection, cardiac disease, significant medical or psychiatric disease/condition that, in the opinion of the Investigator, would interfere with the evaluation of EO2401 or interpretation of patient safety or study results or that would prohibit the understanding or rendering of (i.e. only consent able patients can be enrolled in the study) and compliance with the requirements of the protocol - including (but not limited to):

    1. Bacterial sepsis or other similarly severe infections
    2. > Grade 2 congestive heart failure within 6 months prior to study entry
    3. Uncontrolled or significant cardiovascular disease, including:

    i. Myocardial infarction within 6 months prior to obtaining informed consent ii. Uncontrolled/unstable angina within 6 months prior to obtaining informed consent iii. Diagnosed or suspected congenital long syndrome iv. Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes) d. Stroke within 6 months prior obtaining informed consent e. Concurrent neurodegenerative disease f. Dementia or significantly altered mental status.

  13. Patients with suspected or active autoimmune disorder or known history of an autoimmune neurologic condition (e.g., Guillain-Barré syndrome) Note, patients with vitiligo, type I diabetes mellitus, hypothyroidism due to autoimmune condition only requiring hormone replacement therapy, psoriasis not requiring systemic therapy, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
  14. Patients with history of solid organ transplantation or hematopoietic stem cell transplantation
  15. Patients with history or known presence of tuberculosis
  16. Pregnant and breastfeeding patients
  17. Patients with history or presence of and/or potentially active virus/ virus
  18. Patients who have received live or attenuated vaccine therapy used for prevention of infectious diseases including seasonal (influenza) vaccinations within 4 weeks of the first dose of study drug
  19. Patients with a history of to any present in the pharmaceutical form of medicinal product
  20. Patients under treatment with immunostimulatory or medications, including herbal remedies, or herbal remedies known to potentially interfere with major organ function
  21. Patients with known drug and alcohol abuse
  22. Patients with known or underlying medical or psychiatric condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or obscure the interpretation of toxicity determination or AEs
  23. Patients who have received treatment with any other investigational agent, or participation in another clinical trial (clinical trial including active interventions are prohibited; participation in clinical trials for data collection purposes only are permitted) within 28 days prior to first study treatment administration and during the treatment period. Note, for investigational agents there should be a of at least 28 days, or 5 half-lives if longer, before first study treatment administration
  24. Patients deprived of their liberty or under protective custody or guardianship.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Multiple dose of EO2041 monotherapy followed by continued EO2401 in combination with nivolumab

    Biological: Multiple dose of EO2401

  • Experimental
    Cohort 2

    Multiple dose of EO2041 in combination with nivolumab

    Biological: Multiple dose of EO2401

  • Experimental
    Cohort 3

    Multiple dose of EO2041 in combination with nivolumab and bevacizumab

    Biological: Multiple dose of EO2401

Interventions

  • BiologicalMultiple dose of EO2401

    Multiple dose administration of EO2401 coadministered with or without nivolumab (and bevacizumab, US only) during the priming phase

This study also gives NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of EO2401 Monotherapy, EO2401 in Combination With Nivolumab , EO2401 in Combination With Nivolumab and Bevacizumab

    Incidences of treatment-emergent Serious Adverse Events ( SAEs) using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.

    Time frame: From treatment start up to study end, assessed up to 27.5 months

  2. Safety and Tolerability of EO2401 Monotherapy, EO2401 in Combination With Nivolumab , EO2401 in Combination With Nivolumab and Bevacizumab

    Incidences of treatment-emergent AEs (TEAEs) using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.

    Time frame: From treatment start up to study end, assessed up to 27.5 months

  3. Safety and Tolerability of EO2401 Monotherapy, EO2401 in Combination With Nivolumab , EO2401 in Combination With Nivolumab and Bevacizumab

    Incidences of deaths

    Time frame: From treatment start up to study end, assessed up to 44 months

Secondary outcomes

  1. Evaluation of Survival

    Overall survival, defined as the time interval from the date of first study treatment administration to the date of death due to any cause

    Time frame: From treatment start up to study end, assessed up to 44 months

  2. Assessment of the Immunogenicity of EO2316, EO2317, EO2318 (Three Components of the Therapeutic Vaccine), and Universal Cancer Peptide That Compose EO2401

    At least one positive response (proof of CD8 T cells specific for the EO2401 mimic peptides and/or for the tumor associated antigen (TAA) target peptides) in either of the used immunomonitoring assays (i.e. CD8 T cell expansion in peripheral blood measured by tetramers/flow cytometry, and Spot-Forming Cells by IFN-γ ELISPOT, both methods applied ex vivo, i.e. without prolonged in vitro stimulation and after in vitro stimulation)

    Time frame: 6 weeks after treatment start

07

Results

Posted Nov 28, 2025

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3
Started215326
Completed215326
Not completed000

Outcome measures

PrimarySafety and Tolerability of EO2401 Monotherapy, EO2401 in Combination With Nivolumab , EO2401 in Combination With Nivolumab and Bevacizumab

Incidences of treatment-emergent Serious Adverse Events ( SAEs) using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.

Time frame:
From treatment start up to study end, assessed up to 27.5 months
Reported as:
Count of participants · Participants
Safety and Tolerability of EO2401 Monotherapy, EO2401 in Combination With Nivolumab , EO2401 in Combination With Nivolumab and Bevacizumab
ParticipantsCohort 1Cohort 2Cohort 3
Safety and Tolerability of EO2401 Monotherapy, EO2401 in Combination With Nivolumab , EO2401 in Combination With Nivolumab and Bevacizumab988
PrimarySafety and Tolerability of EO2401 Monotherapy, EO2401 in Combination With Nivolumab , EO2401 in Combination With Nivolumab and Bevacizumab

Incidences of treatment-emergent AEs (TEAEs) using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.

Time frame:
From treatment start up to study end, assessed up to 27.5 months
Reported as:
Count of participants · Participants
Safety and Tolerability of EO2401 Monotherapy, EO2401 in Combination With Nivolumab , EO2401 in Combination With Nivolumab and Bevacizumab
ParticipantsCohort 1Cohort 2Cohort 3
Safety and Tolerability of EO2401 Monotherapy, EO2401 in Combination With Nivolumab , EO2401 in Combination With Nivolumab and Bevacizumab215126
PrimarySafety and Tolerability of EO2401 Monotherapy, EO2401 in Combination With Nivolumab , EO2401 in Combination With Nivolumab and Bevacizumab

Incidences of deaths

Time frame:
From treatment start up to study end, assessed up to 44 months
Reported as:
Count of participants · Participants
Safety and Tolerability of EO2401 Monotherapy, EO2401 in Combination With Nivolumab , EO2401 in Combination With Nivolumab and Bevacizumab
ParticipantsCohort 1Cohort 2Cohort 3
Safety and Tolerability of EO2401 Monotherapy, EO2401 in Combination With Nivolumab , EO2401 in Combination With Nivolumab and Bevacizumab204623
SecondaryEvaluation of Survival

Overall survival, defined as the time interval from the date of first study treatment administration to the date of death due to any cause

Time frame:
From treatment start up to study end, assessed up to 44 months
Reported as:
Median · months
Evaluation of Survival
monthsCohort 1Cohort 2Cohort 3
Evaluation of Survival9.6 (5.9 to 10.8)11.3 (9.0 to 13.7)12.1 (8.0 to 14.8)
SecondaryAssessment of the Immunogenicity of EO2316, EO2317, EO2318 (Three Components of the Therapeutic Vaccine), and Universal Cancer Peptide That Compose EO2401

At least one positive response (proof of CD8 T cells specific for the EO2401 mimic peptides and/or for the tumor associated antigen (TAA) target peptides) in either of the used immunomonitoring assays (i.e. CD8 T cell expansion in peripheral blood measured by tetramers/flow cytometry, and Spot-Forming Cells by IFN-γ ELISPOT, both methods applied ex vivo, i.e. without prolonged in vitro stimulation and after in vitro stimulation)

Time frame:
6 weeks after treatment start
Reported as:
Count of participants · Participants
Assessment of the Immunogenicity of EO2316, EO2317, EO2318 (Three Components of the Therapeutic Vaccine), and Universal Cancer Peptide That Compose EO2401
ParticipantsCohort 1Cohort 2Cohort 3
Assessment of the Immunogenicity of EO2316, EO2317, EO2318 (Three Components of the Therapeutic Vaccine), and Universal Cancer Peptide That Compose EO2401172920

Adverse events

Collected over 44 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 120/21 (95.2%)9/21 (42.9%)20/21 (95.2%)
Cohort 246/53 (86.8%)8/53 (15.1%)51/53 (96.2%)
Cohort 323/26 (88.5%)8/26 (30.8%)26/26 (100%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventCohort 1Cohort 2Cohort 3
Meningitis asepticInfections and infestations2/210/530/26
Condition aggravatedGeneral disorders1/210/530/26
Radius fractureInjury, poisoning and procedural complications1/210/530/26
Bone painMusculoskeletal and connective tissue disorders1/210/530/26
Brain oedemaNervous system disorders1/210/530/26
EpilepsyNervous system disorders1/210/530/26
Motor dysfunctionNervous system disorders1/210/530/26
SeizureNervous system disorders1/210/531/26
Status epilepticusNervous system disorders1/210/530/26
Lower gastrointestinal haemorrhageGastrointestinal disorders0/210/531/26
Most frequent other events
Showing 10 of 241
Most frequent other events
EventCohort 1Cohort 2Cohort 3
Injection site reactionGeneral disorders5/2110/5313/26
Lymphocyte count decreasedInvestigations2/217/5310/26
HeadacheNervous system disorders2/2118/539/26
FatigueGeneral disorders5/2115/538/26
Aspartate aminotransferase increasedInvestigations3/214/538/26
HemiparesisNervous system disorders6/216/535/26
Alanine aminotransferase increasedInvestigations4/217/537/26
SeizureNervous system disorders2/213/537/26
Gamma-glutamyltransferase increasedInvestigations5/213/533/26
Adrenal insufficiencyEndocrine disorders0/210/536/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Total
Median58 (19 to 73)57 (18 to 78)60.5 (24 to 73)58 (18 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Total
Female7211038
Male14321662
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Total
Hispanic or Latino0224
Not Hispanic or Latino19462489
Unknown or Not Reported2507
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Total
American Indian or Alaska Native0000
Asian1012
Native Hawaiian or Other Pacific Islander0101
Black or African American0404
White19482592
More than one race0000
Unknown or Not Reported1001
08

Study locations

10 sites
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Centre Georges François Leclerc
    Dijon, 21000, France
  • Hôpital Pitié-Salpétrière
    Paris, 75013, France
  • Klinik und Poliklinik für Neurologie Universitätsklinikum Bonn
    Bonn, 53105, Germany
  • Universitätsklinikum Frankfurt Goethe-Universität Dr. Senckenbergisches Institut für Neuroonkologie
    Frankfurt am Main, 60528, Germany
  • Neurologische Klinik & Nationales Zentrum für Tumorenerkrankungen Heidelberg Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Medizinische Fakultät Mannheim der Universität Heidelberg
    Mannheim, 68167, Germany
  • Zentrum für Neuroonkologie Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Institit Catala D'Oncologia - Hospital Duran i Reynals
    L'Hospitalet de Llobregat, 8908, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Safety and survival data

Supporting information: Study protocol, Statistical analysis plan

Time frame: Sep 2025

Access criteria: Primary and key secondary outcome measures

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Mar 2024, 43 months.

Results were first posted in Nov 2025, 1 year 8 months after primary completion.

Of 52 industry-sponsored phase 1/2 interventional studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 75. This study's 43 months is below that.

Counting every sponsor, half of 137 studies reached it within 66 months; a quarter within 45 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2019
First posted
Oct 4, 2019
StartActual
Jul 13, 2020
Primary completionActual
Mar 4, 2024
CompletionActual
Mar 4, 2024
Results first posted
Nov 28, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04116658
Lead sponsor
Enterome
Collaborators
Covance
Responsible party
Sponsor
First posted
Oct 4, 2019
Start date
Jul 13, 2020
Primary completion
Mar 4, 2024
Completion
Mar 4, 2024
Results posted
Nov 28, 2025
Last update
Nov 28, 2025

Study contacts

Jean-Michel Paillarse
study director · Enterome

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion